Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etelcalcetide for Calcification Propensity in Dialysis Patients
NCT03795558Phase 2Completed
- Start
- May 2019
- Primary completion
- Dec 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etelcalcetide in secondary hyperparathyroidism (SHPT). Primary endpoint: T50-Laboratory Test for measuring calcification at 32 weeks. Started May 2019; status: completed.
02
Drugs
etelcalcetide
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT03795558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03795558.